Evidence map›Paper›PMID 24097276›Full record

ArticleInternational urology and nephrology2014

Bioengineered kidneys: new sights on a distant horizon.

Christoph Kuppe, Katja Berger, Bart Smeets

Abstract readComment
PubMed Publisher
In one paragraph

Article in International urology and nephrology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

3 authors.

Christoph KuppeDepartment of Nephrology and Immunology, RWTH Aachen University, Pauwelsstrasse 30, 52074, Aachen, Germany.
Katja Berger
Bart Smeets

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The need for renal replacement therapy is currently rising at an annually increasing rate. Current treatment options for patients with end-stage kidney disease include dialysis or organ transplantation. Yet, even though transplant survival has increased due to refined immunosuppressive therapy, morbidity remains high because of organ shortage. Here we discuss a recent publication that describes the transplantation of a bioengineered biocompatible kidney from a decellularized organ scaffold, thus possibly providing a solution to both transplant organ shortage and morbidity associated with long-term immunosuppression.

Indexed as

AnimalsHumansKidneyKidney TransplantationMaleTissue Engineering

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.